

REMARKS***Amendments***

A corrected Abstract of the Disclosure is submitted above, which is to be substituted for the erroneous abstract submitted with the November 6, 2002 Amendment and Response.

Claim 1 has been amended by substituting formula I(b) from claim 3 in place of the structure of formula (I), and all limitations of claims 2 and 3 have been incorporated into claim 1. Claims 2 and 3 have been cancelled as redundant. Claim 13 has been placed in independent form. Otherwise, the claims are of a scope and format as presented with the Amendment and Response dated November 6, 2002.

Status of Claims

Claims 2, 3, 5-12, 14 and 17-19 are allowed. Claims 1 and 16 have been rejected, and claim 13 has been objected to. Following entry of these amendments, claims 1, 5-14 and 16-19 remain pending in this application.

Objection to the Specification

The Examiner objected to the Abstract submitted with the November 6, 2002 Amendment and Response, correctly noting that the text did not correspond to the figure. A replacement Abstract with the correct text is submitted above, which is believed to overcome this objection. Specifically, the replacement Abstract submitted above is identical to the Abstract submitted in and published with PCT Application WO 00/21955, from which the present application derives.

Claim Rejections – 35 U.S.C. § 102

Claims 1 and 16 have been rejected under 35 U.S.C. § 102(b) “as being inherently anticipated by **Myers *et al.*** (WO 95/15758)” for the reasons previously stated and the reasons stated in the present Office Action. In the previously Office Action mailed May 5, 2002, claims 1 and 17 were rejected over Myers, which was said to disclose the compound 4-(3-aminopyrazolyl)-6,7-dimethoxyquinazoline hydrochloride, embraced by formula I. The Examiner there noted that Myers disclosed that such compound is used to treat cellular proliferation and atherosclerosis “which are related to angiogenic and/or vascular permeability.”

Applicants pointed out in the Response of November 6, 2002 that Myers *et al.* is not directed towards angiogenic agents, and that it does not describe inhibitors of vascular endothelial growth factor (VEGF) receptor tyrosine kinase (RTK), but rather is directed toward the inhibition of “CSF-1 and CSF-2 receptor signalling in bone remodeling and haematopoiesis.” Applicants’ detailed arguments on these factors is contained in the Remarks portion of the November 6, 2002 Amendment and Response at pages 24-25. However, this rejection has been maintained in the present Office Action (except applied to composition claim 16 rather than method claim 17), additionally asserting that the CSF-1R kinase mentioned in Myers *et al.* is “one of growth receptor kinases involving in cellular proliferation of cancer, tumor, angiogenesis, etc.” Applicants respectfully submit that the teachings of Myers *et al.* are too remote from the presently claimed method to support an anticipation rejection based on the asserted inherent result of the cited compound.

Nevertheless, in order to expedite the prosecution of this application to allowance, Applicants have incorporated the limitations of allowable claims 2 and 3 into claim 1, thereby entirely obviating this ground for rejection. However, this amendment is being made without abandonment or prejudice to Applicants' right to pursue claims to the cancelled subject matter in one or more continuing applications.

The rejection of composition claim 16 as being inherently anticipated by Myers et al. is not understood, and perhaps was made in error. Claim 16 is directed to a pharmaceutical composition comprising, as the active ingredient, a compound of formula II or pharmaceutically acceptable salt thereof as claimed in any one of claims 18 and 5 to 12, in association with a pharmaceutically acceptable excipient or carrier. Claims 18 and 5 to 12 have already been indicated as being allowable. Certainly a dependent claim cannot be anticipated if each claim upon which it depends allowable. The same would hold true with respect to method claim 17 (rejected for the same ground in the previous Office Action), in that claim 17 is also dependent only any one of claims 18 and 5 to 12.

Conclusion

In view of the foregoing amendments and remarks, it is believed that all claims not previously deemed allowable are in now in condition for allowance. Accordingly, a Notice of Allowance with regard to all pending claims is respectfully requested.


Information Disclosure Statement

The Examiner's attention is called to the further Information Disclosure Statement being filed together with this Amendment and Response. This further Information Disclosure Statement is accompanied by a Form PTO-1449 and a copy of each of the

documents cited thereon. It is respectfully requested that the Examiner consider each of these documents prior to acting upon and allowing the present claims, and acknowledge such consideration by initialing the Form PTO-1449 and returning a copy of same to the undersigned.

EXCEPT for issue fees payable under 37 C.F.R. § 1.18, the Director is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§ 1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account 50-0310. This paragraph is intended to be a CONSTRUCTIVE PETITION FOR EXTENSION OF TIME in accordance with 37 C.F.R. § 1.136(a)(3).

Respectfully Submitted,
Morgan Lewis & Bockius LLP



By:

Donald J. Bird
Registration No. 25,323
Tel. No.: (202) 739-5320
Fax No.: (202) 739-3001

Date: July 29, 2003
Morgan Lewis & Bockius LLP
Customer No. **09629**
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
Tel. No.: 202-739-3000
DJB:mk